This 5%-yielding ASX 200 dividend giant looks like a hidden gem to me

This is a very healthy opportunity in my opinion.

Sonic Healthcare Ltd (ASX: SHL) is an S&P/ASX 200 Index (ASX: XJO) dividend giant, which looks like a hidden gem in my opinion.

How big is the Sonic Healthcare business? It has a market capitalisation of almost $15 billion, according to the ASX. It's one of the larger businesses on the ASX, though it's not quite as large as a company like Woolworths Group Ltd (ASX: WOW) and Telstra Group Ltd (ASX: TLS).

cheap stocks represented by open brief case with golden light shining from it

Image source: Getty Images

What does Sonic Healthcare do?

It's best-known as being a global pathology business. In other words, it's an ASX healthcare share that helps healthcare professionals test patients and figure out what's wrong.

Sonic Healthcare has sizeable operations in a number of countries including the US, Australia, Germany, the UK, Switzerland, Belgium and New Zealand.

The business also has a large radiology division which made $796 million of revenue in FY23. In total, this ASX 200 dividend giant made total revenue of $8.17 billion last financial year.

Why it's a dividend leader

The business has been paying a dividend for a number of decades and it increased the dividend most years. Indeed, the company's leadership has a progressive dividend policy. In other words, the board of directors want to grow the dividend for shareholders, if possible.

There are very few businesses on the ASX that have grown their dividend as frequently as Sonic Healthcare over the last two decades.

The ASX 200 dividend giant is not guaranteed to grow its dividend every year, but I think being in the healthcare sector means the business is defensive enough to perform for income-focused shareholders every year.

It's growing profit with organic growth – it's benefiting from the ageing population tailwind as well as growing populations. Sonic Healthcare also has been steadily making acquisitions, increasing its scale in Australia, the US and Europe.

Sonic Healthcare is also investing in AI, which could help the company's operations and margins in the future.

Dividend yield

In FY23, the business paid a dividend per share of $1.04. That translates into a trailing grossed-up dividend yield of 4.7%.

According to Commsec, the business could pay a dividend per share of $1.071. If it did pay that, this would translate into a forward grossed-up dividend yield of close to 5%.

While it's not the biggest yield around, I like the history of reliability and growth that this ASX 200 dividend giant has offered.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »